S
Slingshot Biosciences
Synthetic cells for drug discovery, clinical trials, and cell therapy manufacturing, ensuring reliable, consistent, and sustainable research
About Slingshot Biosciences
Slingshot Biosciences operates in the biotechnology sector, specializing in the development and distribution of synthetic cells. These synthetic cells are used in various applications including drug discovery, clinical trials, medical testing, and cell therapy manufacturing. The company serves pharmaceutical companies, research institutions, and healthcare providers primarily in North America, including Canada, the United States, and Mexico. Slingshot Biosciences' business model revolves around the direct sale of its synthetic cell products, which are designed to standardize and improve the reliability of research data. The company generates revenue through the sale of these synthetic cells, which are available on-demand or made-to-order, depending on the client's needs. By offering a reliable and sustainable alternative to traditional biological materials, Slingshot Biosciences aims to make healthcare more accessible and equitable globally.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Emeryville, United States
- Employees
- 61
- Open positions
- 10
- Dealroom signal
- 61.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Slingshot Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2023 | $11M | $115M | ARCH Venture Partners · Anterra Capital | ↗ |
| SERIES A✓Equity / VC | Jul 2021 | $23M | $92M | Anterra Capital · ARCH Venture Partners · Northpond Ventures | — |
Growth signals
Latest recorded traffic for Slingshot Biosciences is 5.7K monthly website visits, up 96.6% over the last three months. Slingshot Biosciences's team grew 3.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Northpond Ventures
Anterra Capital
ARCH Venture Partners
Other known investors1 additional known investor
William Hyun
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Slingshot Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Slingshot Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.